Healthcare / Diagnostics & ResearchLSE
$0.42
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-7.4M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-111.6%
↓Gross Margin
N/A
•Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-186.1%
FCF / Net income
1.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.3M · net income $-5.9M · FCF $-6.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.3M | $3.3M | $1.0M | — | — |
| Net Income | $-5.9M | $-5.9M | $-8.7M | $-11.4M | $-8.3M |
| EBITDA | $-5.2M | $-5.2M | $-7.9M | $-10.8M | $-7.9M |
| EPS | -0.03 | -0.03 | -0.05 | -0.07 | -0.06 |
| Operating Margin | -182.9% | -182.9% | -875.3% | — | — |
| Net Margin | -175.9% | -175.9% | -862.2% | — | — |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.15 | 0.06 | — |
| Current Ratio | 0.91 | 0.91 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.2M | $-6.2M | $-7.4M | $-11.4M | $-7.3M |
| Returns | |||||
| ROE | -111.6% | -111.6% | -245.5% | -99.1% | -69.5% |
| Valuation | |||||
| P/B | 18.78 | 18.78 | 497.84 | 164.54 | 597.27 |
| Growth & Yield | |||||
| Revenue Growth | 229.6% | 229.6% | — | — | — |
| EPS Growth | 51.0% | 51.0% | 26.1% | -16.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-69.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.05 → -0.03
Residual
-69.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.